Published in PLoS One on February 28, 2012
High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One (2012) 1.01
Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One (2014) 0.98
Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One (2013) 0.92
The prevalence of hepatitis B virus E antigen among Ghanaian blood donors. Pan Afr Med J (2014) 0.88
Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One (2013) 0.83
Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase. PLoS One (2015) 0.81
Low treatment rates in patients meeting guideline criteria in diverse practice settings. Dig Dis Sci (2014) 0.77
Viral hepatitis: 'Immune tolerance' in HBV infection: danger lurks. Nat Rev Gastroenterol Hepatol (2016) 0.75
A Mechanistic Assessment of the Discordance between Normal Serum Alanine Aminotransferase Levels and Altered Liver Histology in Chronic Hepatitis B. PLoS One (2015) 0.75
HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection. J Clin Exp Hepatol (2015) 0.75
Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol (2016) 0.75
Factors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosis. Sci Rep (2016) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1982) 11.24
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology (2008) 3.26
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 2.79
The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med (2007) 2.52
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut (2005) 2.49
Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem (2000) 2.47
Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology (2010) 2.38
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol (2002) 2.30
Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management. J Gastroenterol Hepatol (2007) 2.00
The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol (2007) 1.73
The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol (2008) 1.71
Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology (2004) 1.52
Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol (2002) 1.49
Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol (2006) 1.41
Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol (2005) 1.33
Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol (2007) 1.28
Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology (2009) 1.27
Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int (2008) 1.23
Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol (2008) 1.18
Liver biopsy findings in chronic hepatitis B. Hepatology (2009) 1.18
A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One (2011) 1.16
The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. Gut (2007) 1.08
Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol (2007) 1.05
A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. J Clin Pathol (2000) 1.00
Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol (2004) 0.99
Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am J Gastroenterol (2008) 0.98
Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol (2008) 0.95
Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther (2005) 0.94
Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol (2010) 0.93
High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat (2008) 0.87
Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. J Viral Hepat (2005) 0.84
Viral hepatitis C. Lancet (2003) 5.81
Viral hepatitis B. Lancet (2003) 4.86
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol (2008) 4.55
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology (2002) 2.90
HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology (2008) 2.84
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology (2003) 2.73
Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology (2013) 2.66
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med (2007) 2.52
Factors associated with seasonal influenza vaccination in Chinese nursing home older adults. J Am Med Dir Assoc (2013) 2.42
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol (2008) 2.24
HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis (2013) 2.11
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology (2011) 1.89
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol (2013) 1.81
SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology (2004) 1.81
A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer (2002) 1.77
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther (2007) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology (2011) 1.74
Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol (2011) 1.73
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol (2013) 1.73
Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis (2008) 1.73
Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol (2011) 1.73
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol (2009) 1.72
Does the addition of endoscopic sphincterotomy to stent insertion improve drainage of the bile duct in acute suppurative cholangitis? Gastrointest Endosc (2003) 1.64
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology (2010) 1.61
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation (2003) 1.61
A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology (2012) 1.60
Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int (2011) 1.60
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol (2004) 1.55
Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol (2011) 1.53
Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology (2003) 1.47
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Chronic hepatitis B--new goals, new treatment. N Engl J Med (2008) 1.42
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology (2009) 1.40
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol (2006) 1.40
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol (2008) 1.36
A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology (2004) 1.34
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology (2007) 1.32
Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother (2011) 1.32
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31
Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol (2009) 1.29
Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol (2008) 1.28
Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology (2004) 1.28